Aardvark Therapeutics, Inc. AARD 深 沪
已收盘 02-06 16:00:00 美东时间
12.65
+1.360
+12.05%
华盛通- 最 高13.03
- 今 开11.61
- 成交量 15.21万股
- 最 低 11.51
- 昨 收 11.29
- 总市值 2.75亿
- 52周最高 19.58
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 4.88
- 委 比 96.40%
- 总股本 2177.33万
- 历史最高 19.58
- 量 比 0.92
- 振 幅 13.46%
- 历史最低 4.88
- 每 手 1
- 风险率 2.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Oppenheimer Initiates Coverage On Aardvark Therapeutics with Outperform Rating, Announces Price Target of $35
Oppenheimer analyst Leland Gershell initiates coverage on Aardvark Therapeutics (NASDAQ:AARD) with a Outperform rating and announces Price Target of $35.
2025-12-23 19:40
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst
Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.
2025-12-13 03:04
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
RBC Capital Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $18
RBC Capital analyst Brian Abrahams maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price target from $19 to $18.
2025-11-14 23:37
Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share
2025-11-14 05:32
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
Aardvark Therapeutics Presents Data At ObesityWeek 2025 Demonstrating Mechanistic Rationale And Therapeutic Potential Of Two Metabolic Obesity Programs, Including ARD-201
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment
2025-11-05 01:02
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek
Aardvark Therapeutics will host an investor webinar on November 5, 2025, to discuss data from ObesityWeek 2025, including ARD-101, ARD-201, and WE-868, and their potential in treating metabolic diseases. The webinar will also cover ARD-101 in Prader-Willi Syndrome. ARD-101, a gut-restricted TAS2R agonist, reduces hunger and is in Phase 3 trials for hyperphagia in PWS. ARD-201, a fixed-dose combination of ARD-101 and a DPP-4 inhibitor, aims to enh...
2025-10-22 12:00
